This study aimed to evaluate and compare the antimicrobial efficacy of CHX and FT mouthwashes against C. albicans and S. sanguinis by measuring the diameters of growth inhibition zones. The findings revealed that CHX exhibited significantly greater inhibitory effects on both C. albicans and S. sanguinis compared to FT.
Our results align with previous studies, such as Farrokhnia et al. (
11), which also found that CHX mouthwash displayed superior antibacterial effects against
Streptococcus mutans compared to FT. Although their study focused on a different bacterial strain, the consistent findings across various microorganisms reinforce the reliability of CHX's broad-spectrum antimicrobial properties.
Furthermore, studies like Ardizzoni et al. (
25) have demonstrated the strong antifungal activity of CHX against
C. albicans, supporting our findings. The superior efficacy of CHX is likely due to its strong binding affinity to microbial cell membranes, which disrupts membrane integrity, increases permeability, and causes intracellular leakage, ultimately inhibiting cell function and proliferation.
Evans et al. (
26) also studied the inhibitory effects of various antiseptic mouthwashes, including CHX, on
S. sanguinis,
S. mutans, and
Lactobacillus acidophilus. Among the mouthwashes tested, CHX, CPC, povidone, and sodium hypochlorite proved the most effective. This study aligns with the current research by examining the effects of both CPC and CHX on
S. sanguinis, further validating CHX’s superior antimicrobial performance.
Furthermore, a recent study by Jain et al. (
27) observed the antimicrobial effects of CHX on
C. albicans and
S. mutans, reporting inhibition zones of 12.4 mm for
C. albicans and 20.85 mm for
S. mutans. These results align with our findings, which indicate CHX’s effectiveness against both tested organisms, with particularly high efficacy against bacterial samples.
A 2020 study by Souza et al. (
28) examined the prevalence of various oral
Candida species in cancer patients and compared the effects of different mouthwashes. While both 5% cetylpyridinium and 0.12% CHX mouthwashes showed acceptable effects against
C. albicans, Souza et al. found 5% cetylpyridinium to be more effective, a result contrasting with our findings. This discrepancy may stem from the lower CHX concentration used in Souza et al.'s study and possible variations in the specific
Candida strains examined.
Chlorhexidine outperforms FT mouthwash due to its superior mechanism of action and broader spectrum of activity (
11,
23,
24,
27). While FT primarily relies on CPC for its antimicrobial properties—effective against certain gram-positive bacteria and exhibiting limited antifungal activity—it does not match CHX's extensive efficacy (
11,
29-
31). Chlorhexidine’s mechanism involves robust adhesion to microbial membranes, significantly disrupting cell integrity and increasing membrane permeability. This action leads to osmotic imbalance and extensive leakage of intracellular contents, making CHX effective against both gram-positive and gram-negative bacteria, as well as fungi. Additionally, CHX’s strong binding within the oral cavity provides a prolonged antimicrobial effect, ensuring a sustained protective environment. By comparison, CPC’s antimicrobial effects are more limited and less durable, positioning CHX as a more comprehensive solution for maintaining oral hygiene (
30-
32).
Despite the strengths of this study, it has a few limitations. First, as a laboratory-based study, it does not account for real-world factors such as retention time in the oral cavity, salivary flow, and interactions with food particles. Second, the study only examined the immediate antimicrobial effects and did not assess the long-term impact of the mouthwashes on oral health. Future studies should include clinical trials to evaluate the effectiveness of these mouthwashes in actual patient populations.
5.1. Conclusions
Based on the findings of this study, CHX mouthwash demonstrated superior efficacy against both C. albicans and S. sanguinis compared to FT mouthwash. For therapeutic purposes, CHX is recommended, while FT may be suitable for daily and adjunctive use. However, further clinical research is needed to validate these results in real-world settings.